Portuguese Journal of Public Health

Research Article

Port J Public Health 2022;40:122–129 DOI: 10.1159/000525885 Received: November 29, 2021 Accepted: July 1, 2022 Published online: August 11, 2022

Prevalence of Self-Medication in Portuguese Adolescents

Inês Almeida^a Clara Rocha^{b, c, d} Jorge Balteiro^a

^aDepartment of Pharmacy, Polytechnic Institute of Coimbra, Coimbra Health School, Coimbra, Portugal; ^bDepartment of Complementary Sciences, Polytechnic Institute of Coimbra, Coimbra Health School, Coimbra, Portugal; ^cDepartment of Electrical and Computer Engineering, INESC Coimbra, University of Coimbra, Coimbra, Portugal; ^dLaboratory for Applied Health Research (LabinSaúde), Coimbra, Portugal

Keywords

 $\label{eq:continuous} Adolescent \cdot Epidemiology \cdot Knowledge \cdot Prevalence \cdot \\ Self-medication$

Abstract

Self-medication is considered one of the health-risk behaviours found among adolescents. The main objective of this study is to determine the prevalence of self-medication for Portuguese adolescents. An observational cross-sectional study was carried out. The sample comprised 420 adolescents, of whom 343 (81.7%; 95% CI: 77.8-85.2) had already self-medicated and 277 (66.0%; 95% CI: 61.4-70.5) self-medicated in the last 6 months. The main health problems that motivated self-medication were headache (76.7%), flu (70.6%), sore throat (56%), and fever (54.5%). Paracetamol was the most consumed drug (86.9%) followed by ibuprofen (83.1%). The pharmacy (87.8%) was the preferred place to purchase drugs; however, 221 adolescents (64.4%) reported that they self-medicated with the medicines they had at home. Of the adolescents who resorted to self-medication, only 59.6% sought additional information about the drug and 53.9% referred to the package leaflet of the medicinal product as the main source of clarification. A significant portion of the respondents (84.3%) believed that self-medication might be acceptable to treat minor illnesses. It was observed that self-medication is a very common practice among adolescents, making it an extremely important issue to carry out more studies on this section of the Portuguese population due to the scarcity of existing ones. These data can be used to define strategies for the dissemination of the rational use of the drug in the adolescent population.

© 2022 The Author(s). Published by S. Karger AG, Basel on behalf of NOVA National School of Public Health

Prevalência da automedicação em adolescentes portugueses

Palavras Chave

Adolescente · Automedicação · Conhecimento · Epidemiologia · Prevalência

Resumo

A automedicação é considerada um dos comportamentos de risco para a saúde encontrado entre os adolescentes. Este estudo teve como principal objetivo determinar

Karger@karger.com www.karger.com/pjp



@ 2022 The Author(s). Published by S. Karger AG, Basel on behalf of NOVA National School of Public Health

This is an Open Access article licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense), applicable to the online version of the article only. Usage and distribution for commercial purposes requires written permission.

Correspondence to: Clara Rocha, clarapr@estescoimbra.pt a prevalência da automedicação de adolescentes portuqueses. Foi realizado um estudo observacional de coorte transversal. A amostra compreende 420 adolescentes, dos quais 343 (81.7%; 95% CI: 77.8-85.2) já se automedicaram e 277 (66.0%; 95% CI: 61.4-70.5) automedicaram-se nos últimos 6 meses. Os principais problemas de saúde que motivaram a automedicação foram a dor de cabeça (76.7%), gripe/constipações (70.6%), dor de garganta (56%) e febre (54.5%). O paracetamol foi o medicamento mais consumido na auto-medicação (86.9%) seguido do Ibuprofeno (83.1%). O local mais referido para a aquisição de medicamentos foi a farmácia (87.8%), no entanto, 221 adolescentes (64.4%) referiram que se automedicam com os medicamentos que têm em casa. Dos adolescentes que recorreram à automedicação, 59.6% procuraram informações ou esclarecimentos adicionais do medicamento e 53.9% referiram a bula como a principal fonte. Uma parte significativa dos inquiridos (84.3%) acredita que a auto-medicação poder ser aceitável para tratar doenças menores. Observou-se que a automedicação é muito comum nos adolescentes portugueses com idades entre 14 e 19 anos, tornando-se importante a definição de estratégias para a divulgação do uso racional do medicamento nesta população.

© 2022 The Author(s). Published by S. Karger AG, Basel on behalf of NOVA National School of Public Health

Introduction

Self-medication is an increasingly frequent phenomenon worldwide. Regardless of the individual's cultural level, historical context, or economic and social status, self-medication has become a common practice [1–3]. It is defined as the use of over-the-counter medications (OTC drugs) by the patient or by the person responsible for him, who decides which drug to use to treat, relieve symptoms, or even promote health [4, 5].

The World Health Organization defends the importance of self-medication responsibility through the use of OTC drugs, to prevent and treat diseases that do not need a medical prescription. However, it is also recognized that responsible self-medication must be accompanied by appropriate health information [6-10].

Although there are medications that can be purchased without a medical prescription, the patient should not misuse them. Because young people, especially adolescents, represent a group strongly predisposed to irrational use of medications, OTC drugs are being misused by this group due to exposure to advertisements and the media. Therefore, self-medication is considered one of the

health risk behaviours found among adolescents [11–14]. The main sources of self-medication are family, friends, neighbours, pharmacy professionals, previously prescribed medications, or suggestions from advertisements in newspapers or magazines.

The practice of self-medication must be based on authentic information under the advice of health professionals to avoid misuse of the medication. Irrational self-medication increases the risk of adverse effects, can waste resources, and increase pathogen resistance [1, 3, 7, 9, 15, 16].

The self-medication behaviour will vary depending on several socioeconomic characteristics, such as educational and economical levels. Higher economic and educational levels allow people not only to have better access to health education but also to have easy access to medicines. The improvement of knowledge, education, and socioeconomic levels and the development of new technologies promote the practice of self-medication worldwide [2, 6, 8, 13, 14].

Although responsible self-medication helps save time and reduce the cost of treatment, it is not risk-free, particularly for certain therapeutic and target groups (children, adolescents, pregnant women, elderly, and chronically ill). Therefore, providing adolescents with appropriate knowledge concerning the use of medication is a necessary measure for responsible self-medication [3, 8, 9, 17].

Despite the widespread use of self-medication among the adolescent population and its potential harm, up-to-date epidemiological data on this subject are scarce in Portugal. Therefore, the study aimed to evaluate the practice of self-medication among Portuguese adolescents between 14 and 19 years old, the various factors influencing it, the main health problems motivating this practice, and the type of drugs used. It is expected that the results obtained will contribute to the reduction of self-medication and lead to the promotion of alert actions concerning the risks of improper use of medicines.

Materials and Methods

A questionnaire based on the cross-sectional study was conducted to assess the practice of self-medication among adolescents and evaluate the factors which are related to this practice. The study lasted for 6 months, and the data collection period lasted from September to December 2018.

The sample was obtained from two public schools in Central Portugal, one urban and the other rural, using the convenience sampling technique. Inclusion criteria were adolescents in secondary school, aged under 20 years. After permission was given by the

Table 1. Distribution of demographic, health, and behavioural variables by gender

Another they be a size of the		Total (n = 420)	420)	Girls (n =	Girls (n = 219; 52.1%)	Boys (n =)	Boys (n = 201; 47.9%)	OR ^a (95% CI)	p value ^b
reference of the control of the cont		u	%		%	u	%	I	
re 174	Age								
st 6 months 147	14–16	256	61.0	105	47.9	86	48.8	0.905 (0.611–1.340)	
Fig. 177 42.1 97 443 80 398 1213 (0.822–1.789) St f months 141 336 7.9 122 55.7 121 60.2 149 68.0 71 35.3 0.866 (0.577–1.299) 69 164 183 174 175 183 0.866 (0.577–1.299) 141 336 184 174 185 0.866 (0.577–1.299) 142 836 181 82.6 170 84.6 1138 (0.869–1.942) 143 81.7 183 196 89.3 147 73.1 1158 (0.869–1.942) 143 81.7 183 196 89.3 147 73.1 1158 (0.869–1.942) 143 81.7 183 196 89.3 147 73.1 1158 (0.869–1.943) 144 7.42.999 145 86.0 169 77.2 108 89.3 147 73.1 1158 (0.869–1.943) 157 66.0 1 169 77.2 108 89.3 147 73.1 1158 (0.869–1.943) 158 81.8 18.7 18.8 18.7 18.8 18.8 18.8 18.	16–19	164	39.0	114	52.1	103	51.2		0.85
st 6 months	Family in healthcare								
st 6 months	Yes	177	42.1	26	44.3	80	39.8	1.213 (0.822–1.789)	0.37
st 6 months at 6 months and 6 months at 6 months at 6 months and 6 months at 6	No	243	57.9	122	55.7	121	60.2		2.0
141 33.6 70 32.0 71 35.3 0.866 (0.577–1.299) 279	Problem disease last 6 months								
279 664 149 680 130 647 351 815 154 174 11.158 (0.689-1.945) 351 817 196 895 147 731 154 (0.689-1.945) 352 813 124 269 572 108 845 147 131 (1.912-4430) 277 660 169 772 108 537 2911 (1.912-4430) 278 660 169 772 108 537 2911 (1.912-4430) 6	Yes	141	33.6	70	32.0	71	35.3	0.866 (0.577–1.299)	0.54
154 1158 (0489-1945) 154 1158 (0489-1945) 154 1158 (0489-1945) 154 154 1158 (0489-1945) 155 165 165 170 184 172 (0489-1945) 183	ON :	279	66.4	149	0.89	130	64.7		
17.0 17.0	Chronic condition								
351 83.6 181 82.6 170 846 343 81.7 196 89.5 147 73.1 3373 (1968-5.781) 77 183 10.5 5.4 26.9 10.5 5.4 26.9 77 183 18.7 10.8 53.7 29.11 (1912-4430) 143 34.0 16.0 10.2 22.8 10.8 53.7 29.11 (1912-4430) 143 34.0 5.0 1.2 6.0 1.2 6.0 1.0	Yes	69	16.4	38	17.4	31	15.4	1.158 (0.689–1.945)	090
343 81,7 196 895 147 73.1 73.1 73.1 73.1 75.6 77.2 108 5.4 2.6 2.6 77.2 108 2.9 77.2 108 2.9 77.2 7.0	No	351	83.6	181	82.6	170	84.6		9
343 343 343 345	SM at least once								
143 18.3 10.5 1	Yes	343	81.7	196	89.5	147	73.1	3.373 (1.968–5.781)	
143 340 169 772 108 537 2911 (1912-4430) 143 340 50 22.8 93 46.3 2911 (1912-4430) 15 16 340 50 22.8 93 46.3 93 46.3 16 341 94 10 96 10 96 10 96 17 18 18 18 18 18 18 18	No	77	18.3	23	10.5	54	26.9		<0.001
SM at least once (Inc.) Girls (in = 343) 772 (in = 343) 108 (in = 343) 231 (1912-4430) SM at least once (in = 343) Girls (in = 196,57.1%) (in = 147,42.9%) (in = 147,42.9%) OR* (95% CI) rd when they are sick and do not self-medicate (in = 124) (in = 196,57.1%) (in = 147,42.9%) (in = 147,42.9%) OR* (95% CI) rev/filtend 124 (in = 36.2) 8.2 (in = 147,42.9%) 8.2 (in = 147,42.9%) OR* (95% CI) revolution the medicines to self-medicate (in = 124) 36.2 (in = 196,57.1%) 4.2 (in = 147,42.9%) 3.4 (in = 147,42.9%) OR* (95% CI) revolution the medicines to self-medicate (in = 124) 36.2 (in = 33.7) 45 2.3 (in = 147,42.9%) 3.4 (in = 147,42.9%) 3.4 (in = 147,2.9%) lygo to obtain the medicines to self-medicate (in = 124,30.2) 3.7 (in = 147,2.2%) 3.2 (in = 13.2%) 3.4 (in = 13.2%) 3.4 (in = 13.2%) lygo to obtain the medicines to self-medicate (in = 124,30.2) 3.2 (in = 124,30.2%) 3.4 (in = 124,30.2%) 3.4 (in = 124,30.2%) 3.4 (in = 12.2%)	SM last 6 months								
Girls Gi	VPS VPS	777	099	169	777	108	53.7	2 911 (1 912–4 430)	
Girls Boys OR* (95% CI) n % n % 1 n % n 1.29 (0.84-2.00) 2 82 41.8 42 28.6 1.80 (1.14-2.84) 4 66 33.7 59 40.1 0.76 (0.49-1.18) 7 45 23 50 34 0.58 (0.36-0.93) 8 178 90.8 123 83.7 1.93 (1.00-3.71) 18 9.2 14 9.5 0.96 (0.46-2.00) 19 6.28 98 66.7 0.84 (0.54-1.01) 11 5.6 17 11.6 0.46 (0.21-1.01) 13 11 5.6 17 11.6 0.46 (0.21-1.01) 13 11 5.6 17 11.4 0.95 0.96 (0.46-2.00) 14 9.2 17 11.6 0.46 (0.21-1.01) 0.96 (0.46-2.00) 15 1.7 1.8 1.7 1.4 0.96 (0.46-2.00) 11	S CN	143	34.0	20 2	22.8	93	46.3	(00:1: 1:0:1)	<0.001
Girls Boys OR* (95% CI) n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % 1.29 (084-2.00) n % 4.2 28.6 1.80 (1.14-2.84) n % 4.0 0.76 (0.49-1.18) 0.75 (0.49-1.18) n 4 4.5 2.3 5.0 3.4 0.56 (0.49-1.18) n 1.12 6.2.8 98 66.7 0.46 (0.24-1.18) n 1.12 5.6 1.7 1.16 0.46 (0.24-1.13) n 1.1 5.6 1.7 1.16 0.46 (0.21-1.01) n 5.2 <t< td=""><td></td><td>2</td><td>2</td><td>8</td><td>0:57</td><td>3</td><td>2</td><td></td><td></td></t<>		2	2	8	0:57	3	2		
(n=196;57.1%) (n=147;42.9%) (n=147;42.9%) n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n % n 1.29 (0.84-2.00) n 4 42 28.6 1.80 (1.14-2.84) n 4 42 28.6 1.80 (1.14-2.84) n 4 45 23 50 34 0.56 (0.49-1.18) n 112 5.6 14 9.5 0.96 (0.46-1.13) 0.96 (0.46-2.00) n 11 5.6 17 11.6 0.46 (0.21-1.31) 0.96 (0.46-2.00) n 11 5.6 17 11.6 0.46 (0.21-1.21) 0.96 (0.46-1.13) n 5 <th< td=""><td></td><td>SM at leas</td><td>Lonce</td><td>Girls</td><td></td><td>Bovs</td><td></td><td>OB^a (95% CI)</td><td>dellieb</td></th<>		SM at leas	Lonce	Girls		Bovs		OB ^a (95% CI)	dellieb
e n % n % n % e 119 60.7 80 54.4 1.29 (0.84-2.00) 2. 82 41.8 42 28.6 1.80 (1.14-2.84) 4 66 33.7 59 40.1 0.76 (0.49-1.18) 7. 45 23 50 34 0.76 (0.49-1.18) 7. 45 23 50 34 0.76 (0.49-1.18) 7. 45 23 50 34 0.76 (0.49-1.18) 7. 45 23 50 34 0.76 (0.49-1.18) 8 178 98 66.7 0.84 (0.54-1.32) 18 9.2 14 9.5 0.96 (0.46-2.00) 18 9.2 14 9.5 0.96 (0.46-2.00) 19 11 5.6 17 11.6 0.46 (0.1-1.32) 11 5.6 17 11.6 0.46 (0.1-1.42) 12 5.2 26.5 49		(n = 343)		(n = 196; 1)	57.1%)	(n = 147; 4)	.2.9%)		
e n % n % n % e n % e n % e n % e n % e n % e n % e n % e n % e n % e n % e n % e n % e n % e n % e n % e n n n e n n n e n n n n e n n n n n e n n n n n n e n n n n n n			;						
6 119 60.7 80 54.4 1.29 (0.84-2.00) 2 82 41.8 42 28.6 1.80 (1.14-2.84) 3.4 66 33.7 59 40.1 0.76 (0.49-1.18) 3 178 90.8 123 83.7 1.93 (0.46-2.09) 3 174 88.8 115 782 2.20 (1.22-3.98) 3 174 88.8 115 782 2.20 (1.22-3.98) 4 52 2.6 8 54 0.46 (0.15-1.42) 5 5 6 41 0.37 (0.09-1.15) 6 112 57.4 69 48.9 1.41 (0.91-2.18) 7 123 62.8 98 6.7 0.46 (0.15-1.42) 8 124 52 2.6 8 5.4 0.46 (0.15-1.42) 9 112 57.4 69 48.9 1.41 (0.91-2.18) 8 12 72 36.9 50 33.5 1.07 (0.68-1.67) 8 12 72 36.9 50 33.5 1.07 (0.68-1.67) 8 12 72 36.9 50 33.5 1.05 (0.47-1.95) 8 12 72 10.3 15 10.6 0.96 (0.47-1.95)		u	%	u	%	и	%		
119 60.7 80 54.4 1.29 (0.84–2.00) 2 82 41.8 42 28.6 1.80 (1.14–2.84) 4 66 33.7 59 40.1 0.76 (0.49–1.18) 7 45 23 50 34 0.58 (0.36–0.93) 8 178 90.8 123 83.7 1.93 (1.00–3.71) 4 123 62.8 98 66.7 0.84 (0.54–1.32) 4 123 62.8 98 66.7 0.84 (0.54–1.32) 5 11 5.6 17 11.6 0.46 (0.21–1.01) 6 17 11.6 0.46 (0.21–1.01) 0.96 (0.46–2.00) 7 17 11.6 0.46 (0.21–1.01) 0.96 (0.46–2.00) 1 1 5.6 49 33.3 0.99 (0.64–1.50) 2 65 33.2 49 33.3 0.99 (0.64–1.42) 3 1.5 6 4.1 0.37 (0.92–1.42) 4 2.0 5	Size Control and Aller	+000	, modico +						
2 82 41.8 42 28.6 1.27 (0.04-2.00) 2 82 41.8 42 28.6 1.28 (0.14-2.84) 4 66 33.7 59 40.1 0.76 (0.49-1.18) 7 45 23 50 34 0.58 (0.36-0.93) 8 178 90.8 123 83.7 1.93 (1.00-3.71) 4 123 62.8 98 66.7 0.84 (0.54-1.32) 18 9.2 14 9.5 0.96 (0.46-2.00) 11 5.6 17 11.6 0.46 (0.21-1.01) 2 65 33.2 49 33.3 0.99 (0.63-1.50) 3 174 88.8 115 78.2 220 (1.22-3.98) 4 5.2 26.5 49 33.3 0.99 (0.63-1.50) 5 2.6 8 5.4 0.46 (0.15-1.42) 6 4 2.0 5 3.4 0.59 (0.16-2.24) 6 5 3.4 0.2	Wildt tiley dsdally do Wilell tiley ale sic	100	-111EGICAGE	011	203	0	2 7 7	(00 c 80) 0c 1	70.0
4 66 33.7 59 40.1 0.00 (0.147-0.97) 7 45 23 59 40.1 0.76 (0.49-1.18) 8 178 90.8 123 83.7 1.93 (1.00-3.71) 4 123 62.8 98 66.7 0.84 (0.54-1.32) 1 18 9.2 14 9.5 0.96 (0.46-2.00) 1 11 5.6 17 11.6 0.46 (0.21-1.01) 3 174 88.8 115 78.2 2.20 (1.22-3.98) 2 65 33.2 49 33.3 0.99 (0.63-1.56) 4 52 26.5 49 33.3 0.99 (0.63-1.56) 5 2.6 8 5.4 0.46 (0.12-1.42) 6 5 3.4 0.59 (0.16-2.24) 7 4 2.0 5 3.4 0.59 (0.16-2.24) 8 5 4 0.50 (0.16-2.24) 0.50 (0.16-2.24) 9 11.2 5 4 <t< td=""><td>Dhaman</td><td>86-1 86-1</td><td>26.0</td><td>ر د د</td><td>71.0</td><td>00</td><td>4:40</td><td>1 80 (1 1 4 2 84)</td><td>0.2/</td></t<>	Dhaman	86-1 86-1	26.0	ر د د	71.0	00	4:40	1 80 (1 1 4 2 84)	0.2/
7 45 53.7 59 40.1 0.00 (0.43-1.10) 7 45 23 50 34 0.58 (0.36-0.93) 8 178 90.8 123 83.7 1.93 (1.00-3.71) 4 123 62.8 98 66.7 0.84 (0.54-1.32) 1 18 9.2 14 9.5 0.96 (0.46-2.00) 1 11 5.6 17 11.6 0.46 (0.21-1.01) 3 174 88.8 115 78.2 2.20 (1.22-3.98) 2 65 33.2 49 33.3 0.99 (0.63-1.50) 4 52 26.5 49 33.3 0.99 (0.63-1.50) 5 2.6 8 5.4 0.46 (0.15-1.42) 6 4 2.0 5 3.4 0.59 (0.62-1.49) 5 2.6 8 5.4 0.46 (0.15-1.42) 6 4 2.0 5 3.4 0.59 (0.16-2.24) 7 36.9 50	Finalliacy Family mombow/friend	+7- 10-	2005	70	0.14	7 5	20.0	1.00 (1.14–2.04)	20.0
8 45 23 50 34 0.38 (0.50-0.93) 8 178 90.8 123 83.7 1.93 (1.00-3.71) 14 123 62.8 98 66.7 0.84 (0.54-1.32) 18 9.2 14 9.5 0.96 (0.46-2.00) 11 5.6 17 11.6 0.46 (0.21-1.01) 3 174 88.8 115 78.2 2.20 (1.22-3.98) 2 65 33.2 49 33.3 0.99 (0.63-1.50) 3 2.6 49 33.3 0.72 (0.45-1.15) 4 5 2.6 49 33.3 0.72 (0.45-1.15) 5 2.6 49 33.3 0.72 (0.45-1.15) 6 4 2.0 5 3.4 0.59 (0.6-2.24) 6 5 3.4 0.59 (0.6-1.42) 0.59 (0.6-2.1.42) 7 3 1.5 6 4.1 0.37 (0.09-1.49) 8 72 36.9 50 50	Family member/mend	57 0	30.4	00 .	33./	90.	- 70.	0.76 (0.49-1.18)	0.20
8 178 90.8 123 83.7 1.93 (1.00-3.71) 4 123 62.8 98 66.7 0.84 (0.54-1.32) 1 18 9.2 14 9.5 0.96 (0.46-2.00) 1 11 5.6 17 11.6 0.46 (0.21-1.01) 3 174 88.8 115 78.2 2.0 (1.22-3.98) 6 33.2 49 33.3 0.99 (0.63-1.50) 7 26.5 49 33.3 0.90 (0.63-1.15) 8 5 2.6 8 5.4 0.46 (0.15-1.42) 9 1.5 6 4.1 0.37 (0.09-1.49) 10 3 1.5 6 4.1 0.37 (0.09-1.49) 10 112 57.4 69 48.9 1.41 (0.91-2.18) 10 10.3 36.9 50 35.5 1.07 (0.68-1.67) 10 10.3 15 10.6 0.96 (0.47-1.95)	Hospital	56	/:/7	42	73	20	34	0.58 (0.36-0.93)	0.03
87.8 178 90.8 123 83.7 1.93 (1.00-3.71) 644 123 62.8 98 66.7 0.84 (0.54-1.32) 9.3 18 9.2 14 9.5 0.96 (0.46-2.00) 8.2 11 5.6 17 11.6 0.46 (0.21-1.01) 84.3 174 88.8 115 78.2 2.20 (1.22-3.98) 33.2 65 33.2 49 33.3 0.99 (0.63-1.56) 29,4 52 26.5 49 33.3 0.72 (0.45-1.15) 2.6 4 2.0 5 3.4 0.46 (0.15-1.42) 2.6 4 2.0 5 3.4 0.59 (0.16-2.24) 2.6 3 1.5 6 4.1 0.37 (0.09-1.49) 53.9 112 57.4 69 48.9 1.41 (0.91-2.18) 36.3 72 36.9 50 35.5 1.07 (0.68-1.67) 34.8 78 40.0 39 27.7 1.74 (1.09-2.78) 10.4 20 10.6 (0.47-1.95) 10.6 0.96 (0.47-1.95)	Where they usually go to obtain the me	edicines to seir-n	nedicate êz ê	ļ	0		1		
64.4 123 62.8 98 66.7 0.84 (0.54-1.32) 93 18 9.2 14 9.5 0.96 (0.46-2.00) 8.2 11 5.6 17 11.6 0.46 (0.21-1.01) 84.3 174 88.8 115 78.2 2.20 (1.22-3.8) 33.2 65 33.2 49 33.3 0.99 (0.63-1.56) 29.4 52 2.6.5 49 33.3 0.72 (0.45-1.15) 3.8 5 2.6 8 5.4 0.46 (0.15-1.42) 2.6 4 2.0 5 3.4 0.59 (0.16-2.24) 2.6 4 2.0 5 3.4 0.59 (0.16-2.24) 2.6 4 2.0 5 3.4 0.59 (0.16-2.24) 2.6 3 1.5 6 4.1 0.37 (0.09-1.49) 2.6 3 1.5 6 4.1 0.37 (0.09-1.49) 3.3 72 36.9 50 35.5 1.74 (1.09-2.78) <tr< td=""><td>Fnarmacy</td><td>301</td><td>8/.8</td><td>8/1</td><td>8.0%</td><td>123</td><td>83./</td><td>1.93 (1.00–3.71)</td><td>0.04</td></tr<>	Fnarmacy	301	8/.8	8/1	8.0%	123	83./	1.93 (1.00–3.71)	0.04
9.3 18 9.2 14 9.5 0.96 (0.46–2.00) 8.2 11 5.6 17 11.6 0.46 (0.21–1.01) 84.3 174 88.8 115 78.2 2.20 (1.22–3.98) 33.2 65 33.2 49 33.3 0.99 (0.63–1.56) 29,4 52 26.5 49 33.3 0.72 (0.45–1.15) 2.6 4 2.0 5 3.4 0.59 (0.16–2.24) 2.6 4 2.0 5 3.4 0.59 (0.16–2.24) 2.6 3 1.5 6 4.1 0.37 (0.09–1.49) 53.9 112 57.4 69 48.9 1.41 (0.91–2.18) 36.3 72 36.9 50 35.5 1.07 (0.68–1.67) 34.8 78 40.0 39 27.7 1.74 (1.09–2.78) 10.4 20 10.3 15 10.6 0.96 (0.47–1.95)	Home	221	64.4	123	62.8	86	66.7	0.84 (0.54–1.32)	0.55
8.2 11 5.6 17 11.6 0.46 (0.21-1.01) 84.3 174 88.8 115 78.2 2.20 (1.22-3.98) 33.2 65 33.2 49 33.3 0.09 (0.63-1.56) 29.4 52 26.5 49 33.3 0.09 (0.63-1.56) 29.4 52 2.6 8 5.4 0.46 (0.15-1.142) 2.6 4 2.0 5 3.4 0.59 (0.16-2.24) 2.6 3 1.5 6 4.1 0.37 (0.09-1.49) 53.9 112 57.4 69 48.9 1.41 (0.91-2.18) 36.3 72 36.9 50 35.5 1.07 (0.68-1.67) 34.8 78 40.0 39 27.7 1.74 (1.09-2.78) 10.4 20 10.3 15 10.6 0.96 (0.47-1.95)	Trading post	32	9.3	18	9.5	14	9.5	0.96 (0.46–2.00)	0.92
84.3 174 88.8 115 78.2 2.20 (1.22-3.98) 33.2 65 33.2 49 33.3 0.99 (0.63-1.56) 29.4 52 26.5 49 33.3 0.72 (0.45-1.15) 3.8 5 2.6 8 5.4 0.46 (0.15-1.42) 2.6 4 2.0 5 3.4 0.59 (0.16-2.24) 2.6 3 1.5 6 4.1 0.37 (0.09-1.49) 53.9 112 57.4 69 48.9 1.41 (0.91-2.18) 36.3 72 36.9 50 35.5 1.07 (0.68-1.67) 34.8 78 40.0 39 27.7 1.74 (1.09-2.78) 10.4 20 10.3 10.6 0.96 (0.47-1.95)	Friend/neighbour/family	28	8.2	11	5.6	17	11.6	0.46 (0.21–1.01)	0.05
84.3 174 88.8 115 78.2 2.20(1.22-3.98) 33.2 65 33.2 49 33.3 0.99 (0.63-1.56) 29.4 52 26.5 49 33.3 0.99 (0.63-1.56) 3.8 5 2.6 8 5.4 0.46 (0.15-1.42) 2.6 4 2.0 5 3.4 0.59 (0.16-2.24) 2.6 3 1.5 6 4.1 0.37 (0.09-1.49) 53.9 112 57.4 69 48.9 1.41 (0.91-2.18) 36.3 72 36.9 50 35.5 1.07 (0.68-1.67) 34.8 78 40.0 39 27.7 1.74 (1.09-2.78) 10.4 20 10.3 15 10.6 0.96 (0.47-1.95)	Main reasons for resorting to SM								
33.2 65 33.2 49 33.3 0.99 (0.63-1.56) 29.4 52 26.5 49 33.3 0.72 (0.45-1.15) 3.8 5 2.6 8 5.4 0.46 (0.15-1.42) 2.6 4 2.0 5 3.4 0.59 (0.16-2.24) 2.6 3 1.5 6 4.1 0.37 (0.09-1.49) 53.9 112 57.4 69 48.9 1.41 (0.91-2.18) 36.3 72 36.9 50 35.5 1.07 (0.68-1.67) 34.8 78 40.0 39 27.7 1.74 (1.09-2.78) 10.4 20 10.3 15 10.6 0.96 (0.47-1.95)	Disease without apparent sever	289	84.3	174	88.8	115	78.2	2.20 (1.22–3.98)	0.01
294 52 26.5 49 33.3 0.72 (0.45-1.15) 3.8 5 2.6 8 5.4 0.46 (0.15-1.42) 2.6 4 2.0 5 3.4 0.59 (0.16-2.24) 2.6 3 1.5 6 4.1 0.37 (0.09-1.49) 53.9 112 57.4 69 48.9 1.41 (0.91-2.18) 36.3 72 36.9 50 35.5 1.07 (0.68-1.67) 34.8 78 40.0 39 27.7 1.74 (1.09-2.78) 10.4 20 10.3 15 10.6 0.96 (0.47-1.95)	Acquire experience	114	33.2	65	33.2	49	33.3	0.99 (0.63–1.56)	0.97
3.8 5 2.6 8 5.4 0.46 (0.15–1.42) 2.6 4 2.0 5 3.4 0.59 (0.16–2.24) 2.6 3 1.5 6 4.1 0.37 (0.09–1.49) 53.9 112 57.4 69 48.9 1.41 (0.91–2.18) 36.3 72 36.9 50 35.5 1.07 (0.68–1.67) 34.8 78 40.0 39 27.7 1.74 (1.09–2.78) 10.4 20 10.3 15 10.6 (0.47–1.95)	Family opinion	101	29.4	52	26.5	49	33.3	0.72 (0.45–1.15)	0.17
2.6 4 2.0 5 3.4 0.59 (0.16–2.24) 2.6 3 1.5 6 4.1 0.37 (0.09–1.49) 53.9 112 57.4 69 48.9 1.41 (0.91–2.18) 36.3 72 36.9 50 35.5 1.07 (0.68–1.67) 34.8 78 40.0 39 27.7 1.74 (1.09–2.78) 10.4 20 10.3 15 10.6 0.96 (0.47–1.95)	Lack of time	13	3.8	2	2.6	8	5.4	0.46 (0.15–1.42)	0.17
2.6 3 1.5 6 4.1 0.37 (0.09-1.49) 53.9 112 57.4 69 48.9 1.41 (0.91-2.18) 36.3 72 36.9 50 35.5 1.07 (0.68-1.67) 34.8 78 40.0 39 27.7 1.74 (1.09-2.78) 10.4 20 10.3 15 10.6 0.96 (0.47-1.95)	Friend opinion	6	5.6	4	2.0	2	3.4	0.59 (0.16–2.24)	0.44
53.9 112 57.4 69 48.9 1.41 (0.91-2.18) 36.3 72 36.9 50 35.5 1.07 (0.68-1.67) 34.8 78 40.0 39 27.7 1.74 (1.09-2.78) 10.4 20 10.3 15 10.6 0.96 (0.47-1.95)	Doctor unavailability	6	2.6	m	1.5	9	4.1	0.37 (0.09–1.49)	0.14
53.9 112 57.4 69 48.9 1.41 (0.91-2.18) 36.3 72 36.9 50 35.5 1.07 (0.68-1.67) 34.8 78 40.0 39 27.7 1.74 (1.09-2.78) 10.4 20 10.3 15 10.6 0.96 (0.47-1.95)	Main sources of information on medicin	nes for SM							
7friend 122 36.3 72 36.9 50 35.5 1.07 (0.68–1.67) 117 34.8 78 40.0 39 27.7 1.74 (1.09–2.78) 35 10.4 20 10.3 15 10.6 0.96 (0.47–1.95)	Package leaflet	181	53.9	112	57.4	69	48.9	1.41 (0.91–2.18)	0.12
117 34.8 78 40.0 39 27.7 1.74 (1.09-2.78) 35 10.4 20 10.3 15 10.6 0.96 (0.47-1.95)	Family member/friend	122	36.3	72	36.9	50	35.5	1.07 (0.68–1.67)	0.78
35 10.4 20 10.3 15 10.6 (0.47–1.95)	Pharmacist	117	34.8	78	40.0	39	27.7	1.74 (1.09–2.78)	0.02
	Internet	35	10.4	20	10.3	15	10.6	0.96 (0.47–1.95)	0.91
		0 0 (2)	- ' . ' - ' - ' - ' - ' - ' - ' - ' - '						

Table 2. Prevalence of the main health problems that motivate self-medication at least once

	n	% (95% CI)
Main health problems ($n = 343$)		
Headache	263	76.7 (72.0-80.9)
Flu/constipation	242	70.6 (65.6-75.2)
Sore throat	192	56.0 (50.7-61.2)
Fever	187	54.5 (49.2-59.7)
Cough and hoarseness	156	45.5 (40.3-50.8)
Runny nose/nasal congestion	129	37.6 (32.6-42.8)
Insect bites	109	31.9 (27.1-36.9)
Muscle pains	96	28.0 (23.4-32.9)
Minor burns	88	25.7 (21.2-30.4)
Stomach aches	83	24.2 (19.9-28.9)
Toothache	64	18.7 (14.8-23.0)
Vomiting	46	13.4 (10.1-17.3)
Anxiety	40	11.7 (8.6-15.3)
Diarrhoea	39	11.4 (8.3-15.0)
Herpes labialis	38	11.1 (8.0-14.7)

directors of the schools of the study, a meeting was held with the directors of each class of the students who agreed to participate and, in the case of minors, with the permission of their parents, to clarify the objectives of this study, as well as to request their collaboration in data collection. All 896 high school students (33 classes) from the study schools were invited to participate. All classes accepted to participate and, overall, 420 students accepted (46.7% student response rate).

Data were collected through a pre-tested semi-structured questionnaire divided into two parts: the first part allows the characterization of the sample, while the second part evaluates the practice and drugs used for self-medication and the factors that influence it. A list of drugs was presented for the participants to indicate which ones they had already used for self-medication, and if any of the drugs were on the list, they could add them. The drugs were then classified according to the Anatomical Therapeutic Chemical Classification System, that is, the ATC classification system (level 1, organs or systems; level 2, therapeutic subgroup; level 5, drug). To verify that the questions were correctly formulated and were well understood by the adolescents, a pre-test was applied to 27 adolescents. The questionnaires were answered by the adolescents, individually and in the presence of the class director, to avoid the exchange of opinions that could influence the answers.

Categorical variables were described by frequency and respective 95% confidence intervals (95% CI) and continuous variables by mean and standard deviation. χ^2 or Fisher's exact test (whenever appropriate) are used for comparison between the categorical variables. Binary logistic regression models were performed to examine the factors related to self-medication in the last 6 months, and the odds ratio (OR) and the respective 95% CI were computed. Associations were considered statistically significant at a p value less than 0.05. Statistical analysis was performed by using software IBM SPSS v.24 (National Opinion Research Center, Chicago, IL, USA) and GraphPad Prism v. 6.04 (La Jolla, San Diego, CA, USA).

Table 3. Prevalence of disadvantages and advantages of this self-medication at least once

	n	% (95% CI)
Main disadvantages ($n = 337$)		
Wrong medicine	171	50.4 (45.1-55.8)
Adverse reactions	166	50.1 (44.8-55.5)
Wrong dose	153	46.0 (40.7-51.3)
Worsening of symptoms	76	23.1 (18.9-27.8)
Mask pathology	77	23.1 (18.9-27.8)
Main advantages ($n = 337$)		
Health care relief	94	27.6 (23.0-32.5)
Time saver	90	26.4 (21.9-31.3)
Economic savings	42	12.5 (9.2–16.3)

Results

The gender-specific main characteristics of the study population are described in Table 1. Of the 420 adolescents questioned, 219 (52.1%) are female and aged between 14 and 19 years, the average being 16.03 ± 1.228 years (mean ± standard deviation). 177 (42.1%) of the adolescents mentioned having a family member working in the health area, 141 (33.6%) revealed a health problem in the last 6 months, and 69 (16.4%) a chronic condition. The prevalence of using at least one drug by self-medication was three times higher in girls (OR = 3.37, 95% CI: 1.97– 5.78). When adolescents were asked about "what they usually do when they are sick," "go to the hospital" was more mentioned by boys (OR = 0.58, 95% CI: 0.36-0.93) and "go to the pharmacy" by girls (OR = 1.80, 95% CI: 1.14-2.84). More than half of the adolescents (64.4%) also reported that they obtain the medicines for self-medication at home. When asked about the main reasons for resorting to self-medication, 84.3% of the adolescents mentioned that they do it when they consider the disease is not serious, and this answer was two times more prevalent in the girls (OR = 2.20, 95% CI: 1.22-3.98). The main health problems that motivate adolescents to self-medicate are headaches (76.7%), followed by flu or colds (70.6%), sore throat (56%), and fever (54.5%), as shown in Table 2.

To obtain information or additional clarifications about the medicines for self-medication, girls were the ones who used pharmacists the most (OR = 1.74, 95% CI: 1.09-2.78), as shown in Table 1. Of the respondents who self-medicated, 74.8% (95% CI: 70.0-79.2) revealed that they were aware of self-medication risks and 97.6% (95% CI: 95.6-98.9) denied having had any problem with self-medication taking.

In Table 3, we can see the main advantages and disadvantages related to self-medication, in adolescents re-

 Table 4. Distribution of pharmaceuticals used for self-medication according to groups and subgroups of Anatomical Therapeutic Chemical (ATC) classification (World Health Organization) by gender

A-dimentary tract and metabolism A-dimentary tract and particular disorders, n(%) A-disorder complex disorders, n(%) D-demandopical and ministerines and entiseptics, n(%) D-demandopical and infectives and antiseptics, n(%) A-disorder complex disorders, n(%) A-disorder di						
96) 15 (16.4) 16 (16.2) 16 (16.4) 17 (21.0) 18 (17.0) 19 (6.1) 19	ATC classification	Total (n = 343)	Girls (n = 196; 57.1%)	Boys (n = 147; 42.9%)	OR ^a (95% CI)	<i>p</i> value
96) 10 (2.9%) 10 (2.9%) 11 (2.5%) 11 (2.5%) 11 (2.5%) 11 (2.5%) 12 (1.6%) 13 (1.5%) 14 (1.4%) 15 (4.4) 15 (4.4) 16 (3.1) 16 (3.1) 16 (3.1) 16 (3.1) 16 (3.1) 16 (3.1) 17 (3.6) 19 (6.1) 18 (8.1) 19 (6.1)	A – alimentary tract and metabolism					
9,9 s and antiflatulents 10(2,9%) 8 (4,1%) 2 (1,4%) 10 (2,9%) 8 (4,1%) 2 (1,4%) 2 (1,4%) 10 (2,9%) 10 (2,9%) 10 (2,9%) 10 (2,9%) 10 (2,9%) 10 (2,9%) 10 (2,9%) 10 (2,9%) 10 (2,9%) 11 (2,2%) 10 (2,9%) 11 (2,2%) 12 (1,2	A01 – stomatological preparations, <i>n</i> (%) A01AD11 – various	56 (16.4)	41 (21.0)	15 (10.2)	2.34 (1.24–4.42)	0.01
Is and antiflatulents 10(2.996) 10(2.996) 10(2.996) 10(2.996) 11(0.596) 11(A02 – drugs for acid related disorders, n (%)	(10)	(0)	2 (0 E)	1 01 (0 00 1 02)	070
al disorders 2 (0.6%) 1 (0.5%) 1 (0.7%) 1 (0.7%) 15 (4.4) 6 (3.1) 9 (6.1) 7 (3.6) 13 (8.8) 4 (1.2) 3 (1.5) 1 (0.7) 14 (1.2) 3 (1.5) 1 (0.7) 15 (7.3) 14 (7.1) 11 (7.5) 17 (3.6) 12 (3.4.0) 18 (9.2) 147 (42.9) 97 (49.5) 50 (34.0) 19 (3.1) 11 (3.2) 7 (3.6) 4 (2.7) 11 (3.2) 11 (3.2) 6 (2.3.6) 1 (0.7) 12 (0.6) 1 (0.5) 1 (0.5) 1 (0.7) 24 (7.0) 18 (9.2) 33 (16.8) 20 (13.6) 25 (6.4) 14 (7.1) 32 (0.5) 17 (2.0) 4 (2.0) 3 (2.0) 27 (2.0) 4 (2.0) 3 (3.1) 114 (33.2%) 63 (32.1) 34 (23.1) 114 (33.2%) 63 (32.1) 34 (23.1) 114 (33.2%) 63 (32.1) 34 (23.1) 115 (38.8) 10.7% 110.	A02AF02 – Ordinary salt combinations and antiflatulents	10 (2.9%)	8 (4.1%)	2 (1.4%)	3.09 (0.65–14.75)	0.20
mmatory/anti-infective agents, n (%) 15 (4.4) 6 (3.1) 9 (6.1) 20 (5.8) 7 (3.6) 13 (8.8) 4 (1.2) 3 (1.5) 1 (0.7) 10 (%) 11 (3.2) 147 (42.9) 97 (49.5) 50 (34.0) 123 (35.9) 83 (42.3) 40 (27.2) 113 (35.9) 83 (42.3) 40 (27.2) 113 (35.9) 83 (42.3) 40 (27.2) 114 (3.2) 7 (3.6) 4 (2.7) 115 (32.7) 10.5) 1 (0.7) 110 (3.2) 1 (0.5) 1 (0.7) 110 (3.2) 1 (0.5) 1 (0.7) 111 (3.2) 2 (0.6) 1 (0.5) 1 (0.7) 112 (3.2) 33 (16.8) 20 (13.6) 113 (3.2) 22 (6.4) 14 (7.1) 8 (5.4) 114 (3.3.2%) 41 (2.0) 25 (13.9) 27 (18.9) 27 (18.9) 27 (18.9) 25 (17.0)	A03 – drugs for functional gastrointestinal disorders A03AX13 – silicones	2 (0.6%)	1 (0.5%)	1 (0.7%)	0.75 (0.05–12.07)	1.00
15 (44) 6 (3.1) 9 (6.1) 15 (44) 6 (3.1) 9 (6.1) 20 (5.8) 7 (3.6) 13 (8.8) 4 (1.2) 3 (1.5) 1 (0.7) 10 ods and ulcers, n (%) 11 (3.2) 14 (7.1) 11 (7.5) 11 (3.2) 123 (35.9) 83 (42.3) 40 (27.2) 11 (3.2) 13 (35.9) 83 (42.3) 40 (27.2) 11 (3.2) 13 (35.9) 83 (42.3) 40 (27.2) 11 (3.2) 13 (3.6) 4 (2.7) 12 (3.6) 1 (0.5) 1 (0.7) 13 (3.6) 2 (3.6) 1 (0.7) 14 (7.0) 1 (0.5) 1 (0.7) 15 (8.3) 1 (10.5) 1 (0.7) 16 (4.1) 2 (2.0) 17 (2.0) 2 (3.6) 175 (89.3) 123 (83.7) 18 (3.2) 22 (6.4) 14 (7.1) 8 (5.4) 19 (28.3) 63 (32.1) 34 (23.3) 27 (18.9) 27 (18.9) 27 (18.9) 25 (17.0)	A06 – drugs for constipation, n (%)					
26 (5.8) 7 (3.6) 13 (8.8) (1.2	A06AB02 – bisacodyl A07 – antidiarhoeals intectinal anti-inflammatom/anti-infective agents n (%)	15 (4.4)	6 (3.1)	9 (6.1)	0.49 (0.17–1.39)	0.19
antiseptics, n (%) antiseptics, n (%) 14 (7.1) 25 (7.3) 14 (7.1) 11 (7.5) 11 (7.5) 123 (3.5) 31 (42.9) 32 (3.6) 123 (3.5) 32 (3.6) 32 (3.6) 32 (3.6) 32 (3.6) 32 (3.6) 32 (3.6) 32 (3.6) 32 (3.6) 32 (3.6) 32 (3.6) 32 (3.6) 33 (16.8) 33 (16.8) 34 (2.0) 35 (15.5) 36 (3.1) 37 (2.0) 37 (2.0) 37 (2.0) 37 (18.9) 38 (3.1) 38 (3.1) 38 (3.1) 38 (3.1) 39 (2.2) 42 (7.0) 42 (7.0) 31 (18.3) 32 (18.3) 33 (18.3) 34 (2.3) 34 (2.3) 34 (2.3) 34 (2.3) 35 (13.2) 37 (18.9) 37 (18.9) 37 (18.9) 37 (18.9) 37 (18.9) 37 (18.9) 37 (18.9) 37 (18.9) 37 (18.9) 37 (18.9) 38 (17.0)	AV7 — antudiamioeas, intestina anti-inimaminatory/anti-iniective agents, ir (%)	20 (5.8)	7 (3.6)	13 (8.8)	0.38 (0.15-0.98)	0.04
nds and ulcers, n (%) 147 (42.9) 197 (49.5) 197 (49.5) 10 (34.0) 113 (35.9) 113 (35.9) 113 (35.9) 113 (35.9) 114 (7.1) 11 (7.5) 113 (35.9) 113 (35.9) 114 (7.1) 115 (32.0) 115 (32.3) 115 (32.3) 115 (32.3) 115 (32.3) 115 (32.3) 117 (32.7) 118 (32.1) 118 (32.1) 118 (32.1) 118 (32.1) 119 (32.1) 119 (32.1) 119 (32.1) 119 (32.1) 119 (32.1) 119 (32.1) 119 (32.1) 119 (32.1) 119 (32.1) 119 (32.1) 119 (32.1) 119 (32.1) 127 (18.9) 127 (18.9) 127 (18.9)	A 12 – mineral supplements, n (%) A 12BA 01 – potassium chloride	4 (1.2)	3 (1.5)	1 (0.7)	2.27 (0.24–22.04)	0.64
nds and ulcers, n (%) 147 (42.9) 17 (42.9) 197 (49.5) 197 (49.5) 198 (42.3) 199 (49.5) 199 (49.	D – dermatological D01 – antifunciale for dermatological use in (%)					
nds and ulcers, n (%) Indesthetics etc., n	D01AC01 – cintimagais fol definatorogical use, // (%)	25 (7.3)	14 (7.1)	11 (7.5)	0.95 (0.42–2.16)	0.51
antiseptics etc., n (%) 123 (35.9) 13 (35.9) 13 (35.9) 13 (32.3) 11 (3.2) 12 (3.4) 13 (3.4) 13 (3.4) 14 (3.1) 14 (3.1) 14 (3.1) 17 (3.2) 18 (3.2) 19 (2.8) 11 (3.2) 11 (3.2) 11 (3.2) 11 (3.2) 11 (3.2) 12 (3.4) 12 (3.4) 13 (3.1) 14 (3.1) 14 (3.1) 17 (3.2) 18 (3.2) 19 (3.3) 19 (3.3) 11 (3.2) 11 (3.2) 11 (3.2) 12 (3.3) 13 (3.3) 14 (3.2) 17 (3.6) 18 (3.2) 19 (3.3) 19 (3.3) 10 (3.3) 10 (3.3) 11 (3.3) 11 (3.3) 12 (18.9) 13 (17.0)	D03 – preparations for treatment of wounds and ulcers, <i>n</i> (%) D03AXO3 – dexnanthenol	147 (42 9)	97 (49 5)	50 (34 0)	1.90 (1.22–2.96)	000
antiseptics, n (%) 11 (3.2) 7 (3.6) 7 (3.6) 1 (2.7) natic products, non-steroids, n (%) 112 (32.7) 112 (32.7) 112 (32.7) 112 (32.7) 112 (32.7) 113 (80.3) 114 (80.3) 115 (85.2) 118 (80.3) 118 (80.3) 119 (85.2) 110 (0.7) 110 (0.5) 110 (0.7) 110 (0.5) 110 (0.7) 110 (D04 – antiprurities, incl. antihistamines, anaesthetics etc., n (%))
antiseptics, n (%) 11 (3.2) 12 (3.6) 13 (4.27) 14 (2.7) 15 (85.2) 118 (80.3) 112 (3.2.7) 2 (0.6) 1 (0.5) 1 (0.5) 1 (0.7) 2 (0.6) 1 (0.5) 1 (0.7) 2 (0.6) 1 (0.5) 1 (0.7) 2 (0.6) 1 (0.5) 1 (0.7) 2 (0.6) 1 (0.5) 1 (0.7) 2 (0.6) 1 (0.5) 1 (0.7) 2 (0.6) 1 (0.5) 1 (0.7) 2 (0.6) 1 (0.5) 1 (0.7) 2 (0.6) 1 (0.5) 1 (0.7) 2 (0.6) 1 (0.5) 1 (0.7) 2 (0.6) 1 (0.5) 1 (0.7) 2 (1.0.7) 2 (1.0.7) 3 (1.0.8) 2 (1.0.7) 2 (1.0.7) 3 (1.0.8) 2 (1.0.9) 3 (2.0) 2 (1.0.9) 4 (2.0) 2 (1.0.9) 2 (1.0.9) 2 (1.0.9) 2 (1.0.9) 2 (1.0.9) 2 (1.0.9) 2 (1.0.9) 2 (1.0.9) 2 (1.0.9) 2 (1.0.9)		123 (35.9)	83 (42.3)	40 (27.2)	1.97 (1.24–3.12)	0.00
ole 11 (3.2) 7 (3.6) 4 (2.7) ry and antirheumatic products, non-steroids, n (%) ry and antirheumatic products, non-steroids, n (%) and antirheumatic products, non-steroids, n (%) for joint and muscular pain, n (%) and antipyretics, n (%) antipyretics, n (%) are radix are radix are radix be radix are radi	antiseptics,					
ry and antirheumatic products, non-steroids, n (%) 112 (32.7) 112 (32.7) 112 (32.7) 112 (32.7) 2 (0.6) 110 (5.3) 1 (0.5) 1 (0.5) 1 (0.7)	G01AF02 – clotrimazole	11 (3.2)	7 (3.6)	4 (2.7)	1.32 (0.38–4.61)	0.76
285 (83.1) 159 (85.2) 118 (80.3) 10 fenac lofenac lofe	M – musculoskeletal system M01A – anti-inflammatory and antirhelimatic products non-steroids. n (%)					
lofenac lofena	M01AE01 – ibuprofen	285 (83.1)	159 (85.2)	118 (80.3)	1.42 (0.80–2.49)	0.23
reducts for joint and muscular pain, n (%) reducts for joint and muscular pain, n (%) reducts for joint and muscular pain, n (%) sections and antipyretics, n (%) redicacid actamol, combinations excl. psycholeptics and sedatives, n (%) redicacid 24 (7.0) 2 (0.6) 1 (0.5) 1 (0.7) 2 (0.6) 1 (0.7) 1 (0.7) 2 (13.6) 2 (13.6) 2 (13.6) 2 (13.6) 2 (1.3) 2 (13.6) 2 (1.1) 2 (1.3) 2 (1.3) 3 (2.0) 3 (2.0) 3 (2.0) 4 (2.0) 3 (2.0) 4 (2.0) 3 (2.0) 4 (2.0) 3 (2.1) 4 (2.1) 3 (2.3) 4 (2.3) 4 (2.3) 6 (4.1) 2 (18.9) 2 (17.0) 2 (17.0)	M01AB05 – diclofenac M01AX17 – nimesulide	112 (32.7) 2 (0.6)	62 (31.6) 1 (0.5)	50 (34.0)	0.90 (0.57–1.42)	0.64
rehiprofen 2 (0.6) 1 (0.5) 1 (0.7) lesics and antipyretics, n (%) cylic acid acetamol, combinations excl. psycholeptics 298 (86.9) 175 (89.3) 123 (183.7) and sedatives, n (%) and sedatives, n (%) ations, n (%) metazoline ous ations, n (%) horobenzyl alcohol 114 (33.2%) 63 (32.1) 34 (23.1) and ordicines, n (%) 62 (18.1) 27 (18.9) 25 (17.0) 62 (18.1) 27 (18.9) 25 (17.0)	M02A – topical products for joint and muscular pain, n (%)	(0:0) 2	(0:0)	(2:0)	(20:21	
esics and antipyretics, n (%) cylic acid acetamol, combinations excl. psycholeptics acetamol, combinations excl. psycholeptics acetamol, combinations excl. psycholeptics 298 (86.9) 175 (89.3) 123 (83.7) 24 (7.0) 18 (9.2) 6 (4.1) ations, n (%) metazoline ous 7 (2.0) 7 (2.0) 7 (2.0) 7 (2.0) 7 (2.0) 7 (2.0) 7 (2.0) 7 (2.0) 14 (7.1) 8 (5.4) 114 (33.2%) 7 (36.2%) 43 (23.1) 114 (33.2%) 62 (18.1) 27 (18.9) 27 (18.9) 28 (17.0)	flurbiprofen	2 (0.6)	1 (0.5)	1 (0.7)	0.75 (0.05–12.07)	1.00
53 (15.5) 33 (16.8) 20 (13.6) 298 (86.9) 175 (89.3) 123 (83.7) and sedatives, n (%) 24 (7.0) 18 (9.2) 6 (4.1) ations, n (%) 7 (2.0) 4 (2.0) 3 (2.0) netazoline 22 (6.4) 14 (7.1) 8 (5.4) nous 97 (28.3) 63 (32.1) 34 (23.1) nlorobazyl alcohol 97 (28.3) 63 (32.1) 43 (29.3%) nlorobazyl alcohol 114 (33.2%) 71 (36.2%) 43 (29.3%) nhorobazyl alcohol 27 (18.9) 25 (17.0)	N – nervous system NO2R – other analgesics and antinvretics in (%)					
acetamol, combinations excl. psycholeptics 298 (86.9) 175 (89.3) 123 (83.7) and sedatives, n (%) 24 (7.0) 18 (9.2) 6 (4.1) (4.1) ations, n (%) 7 (2.0) 7 (2.0) 7 (2.0) 7 (2.0) 14 (7.1) 8 (5.4) artions, n (%) 97 (28.3) 63 (32.1) 114 (33.2%) 97 (38.3) 63 (32.1) 34 (23.1) old medicines, n (%) 62 (18.1) 27 (18.9) 25 (17.0)	N02BA01 – salicylic acid	53 (15.5)	33 (16.8)	20 (13.6)	1.10 (0.60–2.04)	0.88
and sedatives, n (%) 18 (9.2) 6 (4.1) berianae radix 24 (7.0) 18 (9.2) 6 (4.1) attions, n (%) 7 (2.0) 4 (2.0) 3 (2.0) ous 22 (6.4) 14 (7.1) 8 (5.4) rations, n (%) 97 (28.3) 63 (32.1) 34 (23.1) hlorobenzyl alcohol 114 (33.2%) 71 (36.2%) 43 (29.3%) ndl medicines, n (%) 62 (18.1) 27 (18.9) 25 (17.0)	N02BE51 – paracetamol, combinations excl. psycholeptics	298 (86.9)	175 (89.3)	123 (83.7)	1,63 (0.87–3.05)	0.10
ations, n (%) metazoline ous rations, n (%) rations	N05C – hypnotics and sedatives, <i>n</i> (%) N05CM00 - ಬ್ರಾಮ್ಯಾಮ್ಯಾಪ್ನಿಗ್ರಾಟ್ಕ	(07) 80	(0,0)	6 (4.1)	7 30 (0 0) 6 15)	700
ations, n (%) metazoline 22 (6.4)	Noocwoo – valenanae nauk R – respiratory system	(0.1) +2	10 (3.2)	(1:+)0	2.30 (0.32-0.13))
7 (2.0)	R01 – nasal preparations, <i>n</i> (%)					
97 (28.3) 63 (32.1) 34 (23.1) 114 (33.2%) 71 (36.2%) 43 (29.3%) 62 (18.1) 27 (18.9) 25 (17.0)	R01AA05 – oxymetazoline R01AY10 – various	7 (2.0)	4 (2.0)	3 (2.0)	1,00 (0.22–4.54)	1.00
97 (28.3) 63 (32.1) 34 (23.1) 114 (33.2%) 71 (36.2%) 43 (29.3%) 62 (18.1) 27 (18.9) 25 (17.0)	R02 – throat preparations, n (%)	(4:0) 77	(1.7)+-	(t:c) o	(02.0-00.0) +0.1	0.0
	R02AA03 – dichlorobenzyl alcohol	97 (28.3)	63 (32.1)	34 (23.1)	1.57 (0.97–2.56)	0.07
62 (18.1) 27 (18.9) 25 (17.0)	R02AX01 – flurbiproten R05 – couch and cold modicines in (%)	114 (33.2%)	71 (36.2%)	43 (29.3%)	1.37 (0.87–2.18)	0.18
	R05CB02 – bromhexine	62 (18.1)	27 (18.9)	25 (17.0)	1.14 (0.65–1.99)	99.0
K06 – antihistamines for systemic use, n (%) BD6AX27 – declaratadina 25 (17 0) 15 (19 0)	R06 – antihistamines for systemic use, <i>n</i> (%) مربادیت مربطینات میرادیتهای ایرادیات از ایرادیات ایرادیات ایرادیات ایرادیات ایرادیات ایرادیات ایرادیات ایرادیات	(45 (10 0)	(1000)	75 (17 0)	1 25 (0 72_2 18)	0.43
	ווסטעעבי – עבאסומממווים	(0.61) 00	(+:05) 0+	(0.11) C2	(01.2_2,0)	7:0

^a OR, odds ratio by gender (girls/boys).

ferred to. The main advantages mentioned were the contribution not to overload health services (27.6%) and saving time in solving the health problem (26.4%). Half of the adolescents (50.4%) reported that taking the wrong medication can be a disadvantage and not being able to identify possible adverse reactions (50.1%).

Prevalence of self-medication use by medication class and most frequently used drugs. A total of 1,829 medicines were recorded in the study sample. Of these, drugs act on the musculoskeletal system (M00, 21.9%), nervous system (N00, 20.5%), respiratory system (R00, 20.1%), and skin (D00, 16.1%) were most frequently used. In contrast, genitourinary system and sex hormones (G00, 0.6%) were used much less frequently.

As shown in Table 4, the most frequently used medicines were paracetamol, combinations excl. psycholeptics (N02BE51) were reported by 86.9% of the adolescents, followed by ibuprofen (M01AE01) with 83.1%. They were followed by the preparations for the treatment of wounds and ulcers, dexpanthenol (D03AX03) and dimentidene (D04AA13) with 42.9% and 35.9%, respectively, flurbiprofen (R02AX01) reported by 33.2% of adolescents and diclofenac (M01AB05) with 32.7%. Girls were significantly more likely to use A01AD11 – various (OR = 2.34; 95% CI: 1.24–4.42), D03AXO3 –dexpanthenol (OR = 1.90; 95% CI: 1.22–2.96), and D04AA13 – dimetindene (OR = 1.97; 95% CI: 1.24–3.12) than boys. Boys, on the other hand, used significantly more A07DA03 – loperamide (OR = 0.38; 95% CI: 0.15–0.98) than girls.

Prevalence of Self-Medication in the Last 6 Months

Regarding the prevalence of self-medication in the last 6 months, 277 (66.0%; 95% CI: 61.4-70.5) of the adolescents admitted this practice. As suggested by results of binary logistic regression, only gender and having medicines available at home were having significant association with the prating of self-medication in the last 6 months by adolescents. The prevalence is higher in girls (OR = 2.40, 95% CI: 1.35-4.26; p = 0.00) and those who have medicines at home (OR = 2.56, 95% CI: 1.44-4.56; p = 0.00). Although there was no significant association of age with self-medication in the last 6 months, the oldest are the ones who are most aware of the existence of risks associated with self-medication (OR = 0.57, 95% CI: 0.33-0.97), as well as the important role of health professionals in providing advice and clarifying doubts (OR = 0.59; 95% CI: 0.38-0.93). They are also the ones who most recognize the advantage of not overloading health services (OR = 0.59; 95% CI: 0.36-0.95) and the disadvantage of masking other pathologies (OR = 0.37; 95% CI:

0.22–0.62). It was also found that female adolescents are the ones who least recognize self-medication the faster response to the problem (OR = 0.48; 95% CI: 0.29–0.78) and a greater risk of dose error (OR = 0.62; 95% CI: 0.40–0.96).

Discussion

In our study, a very high prevalence of self-medication at least once (81.7%; 95% CI: 77.8–85.2) was found among adolescents aged 14–19 years. Lower values were reported by Abahussain et al. [18] (92%), Shehnaz et al. [19] (89.2%), and Westerlund et al. [20] (88%), in adolescents in the same age group. In contrast, the percentage reported by Moraes et al. [21] was 52.6% and Silva and Giuliani's [22] was even lower at 12.3%. We also found a higher prevalence of self-medication in girls, similar to what has been reported in other studies [7, 23]. It is important to note that the abuse of medications by adolescents can be aggravated by their ease of access and lack of adult supervision, in a group that asserts its autonomy in the practice of self-medication by not consulting a doctor or health professional previously [7, 15].

Of all medicines used (n = 1,829), non-steroid antiinflammatory and antirheumatic products (21.8%), analgesics/antipyretics (19.1%), and throat preparations (11.5%) were the therapeutic groups most used for selfmedication, with paracetamol and ibuprofen being the most consumed medicines. Also, in a study carried out in 2016 in Taiwan with 6,226 adolescents, the most commonly reported drugs for self-medication were non-steroidal anti-inflammatory drugs (31.1%), cough or cold medication (21.6%), and analgesics (19.3%) [24]. These results are in line with other published studies that confirm these therapeutic groups as the most used in selfmedication [4, 7, 11, 15, 23]. It is important to emphasize that the consumption of analgesics/antipyretics/anti-inflammatory drugs is favoured by the ease of purchase since they are OTC drugs. Adolescents use medicines without a prescription on the assumption that they have sufficient knowledge to take responsibility for making decisions and taking care of their health. Therefore, it is of utmost importance that they are properly informed and educated for their correct use.

More than two-thirds of the adolescents in our sample reported that self-medication is used for headaches (76.7%) and flu/cold (70.6%), and more than half report sore throat (56%) and fever (54.5%), which is consistent with the most frequently used drugs reported by them.

Our results support those of other research studies showing the widespread use of analgesics for self-medication [5, 7, 13, 14, 23]. The prevalence of pain among adolescents has been identified as a major public health problem, with an estimated 15%–25% of adolescents suffering from chronic or recurrent pain, such as headaches and abdominal pain [25]. It is of utmost importance to enlighten young people about the importance of proper diagnosis and treatment of pain to prevent persistent or recurrent conditions to avoid overuse of analgesics.

When designing an intervention scheme to promote safe self-medication practice, understanding the sources of information is very helpful. In our study, although 87.8% of adolescents reported going to the community pharmacy to purchase medications for self-medication practice, only 34.8% reported the pharmacist as a source of information, and no other health professionals were mentioned. In comparison, in the study conducted in Taiwan [24], a higher percentage of pharmacist involvement was observed at 82.9%. The importance that health professionals, particularly pharmacy professionals, have in transmitting knowledge about the rational use of medicines is particularly important in adolescents who, in general, do not have enough knowledge to detect the health problem, nor to decide which medicine to use, the correct dose, and dosage [23, 24, 26-28].

Helal and Abou-ElWafa (2017) report that the main reasons for self-medication are the disease without apparent severity (73.9%) and the experience acquired previously (71.4%), in agreement with the present study (84.3%) that revealed the disease with no apparent severity as the main reason for adolescents to resort to self-medication, followed by previously acquired experience (33.2%) [17]. Shehnaz et al. [7] explain the high prevalence of self-medication in adolescents due to the easy access to the medication they have at home. In the present study, more than half of the adolescents report that they have medication at home, facilitating self-medication.

Despite the contributions of the present study, some limitations should be mentioned. With the use of self-reported data in this work, the possibility of information bias cannot be discarded. Self-report may be affected by forgetfulness errors and under-reporting of drug use when adolescents intentionally omit the use of certain drugs or do not know which medicines they had used. Thus, there is a possibility that adolescents' self-medication is higher than what this study reports.

In addition, as a result of not considering clustering effects in the analysis, the conclusions obtained did not take into account robust standard errors, with the risk of having obtained confidence intervals with underestimated amplitude. On the other hand, possible unjustified results may have occurred in the bivariate associations, as the impacts of confounding factors were not considered in this analysis, thus limiting the generalizability of our results to the overall population of teenagers.

Finally, in this article, it is not possible to make inferences about causality, since the objective of this work was to describe the self-medication of Portuguese adolescents, and, as such, other variables identified as significant by other authors were not measured in the study, which can influence self-medication, for example, financial conditions [4], family practices and maternal education [7], and non-use of private health services [4, 7]. More research is needed to explore the influence of these and/or other variables.

Conclusion

This paper aimed to ensure a better understanding of the attitudes of Portuguese adolescents aged 14-19 years towards the use of self-medication. Our results showed that its prevalence was high, being higher in girls. It would be advisable to pay more attention to this public, health concern and promote initiatives such as mass media campaigns and address these issues within the school health education project to make young people more aware of irresponsible consumption of medicine risks without doctor supervision. The study found out that the drug package insert and pharmacists are the main sources of information for self-medication. Since pharmacists have the professional capacity to provide personalized services and advice on medication use, schools should strengthen cooperation with pharmacists and encourage the promotion of activities to educate parents and adolescents about the correct use of medicines.

As analgesics were the most commonly used drugs in this population, we suggest that future studies collect more detailed data on their use. An extended investigation of younger adolescents and children should also be done.

Acknowledgements

This work has been partially supported by project grant UIDB/00308/2020.

Statement of Ethics

The investigation scheme was approved by the ESTeSC – Coimbra Health School Scientific Committee, and authorization was also requested from the directors of the school groups to which the adolescents in the study belonged. The anonymity and confidentiality of the collected data were guaranteed, and parents or legal guardians of participants signed informed consent before the study. The authors declare that they complied with ethical principles according to the Declaration of Helsinki.

Conflict of Interest Statement

The authors have no conflicts of interest to declare.

Author Contributions

Conception, design of the study, final approval of the version to be published, and agreement to be accountable for all aspects of the work ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: I.A., C.R., and J.B.; acquisition of data for the work and drafting of the work: I.A.; analysis and interpretation of data: I.A. and C.R.; critical revision for the important intellectual content of the manuscript: I.A. and J.B.

Data Availability Statement

The data that support the findings of this study are available on request.

References

- 1 Silva FM, Goulart FC, Lazarini CA. Caracterização da prática de automedicação e fatores associados entre universitários do curso de Enfermagem. Rev Eletr Enferm. 2014;16(3): 644–51
- 2 Albusalih F, Naqvi A, Ahmad R, Ahmad N. Prevalence of self-medication among students of pharmacy and medicine colleges of a public sector university in Dammam City, Saudi Arabia. Pharmacy. 2017;5(3):51.
- 3 Bennadi D. Self-medication: a current challenge. J Basic Clin Pharm. 2014;5(1):19–23.
- 4 Matos JF, Pena DAC, Parreira MP, Santos TC, Coura-Vital W. Prevalência, perfil e fatores associados à automedicação em adolescentes e servidores de uma escola pública profissionalizante. Cad Saúde Coletiva. 2018;26(1):76– 83
- 5 Silva IM, Maria A, Catrib F. Automedicação na adolescência: um desafio para a educação em saúde. Cien Saude Colet. 2011;16(1): 1651–60.
- 6 Gupta SB, Imtiaz D, Shrotriya VP, Singh AK. A comparative study on the reasons for use and non-use of self-medication among students of a medical college in Western Uttar Pradesh. Natl J Community Med. 2016;7(1): 25–8
- 7 Shehnaz SI, Agarwal AK, Khan N. A systematic review of self-medication practices among adolescents. J Adolesc Heal. 2014; 55(4):467–83.
- 8 Beyene A, Getachew E, Doboch A, Poulos E, Abdurahman K, Alebachew M. Knowledge, attitude and practice of self-medication among pharmacy students of Rift Valley University, Abichu Campus, Addis Ababa, Ethiopia. J Heal Med Informatics. 2017;8(3):1–6.
- 9 Kasulkar AA, Gupta M. Self-medication practices among medical students of a private institute. Indian J Pharm Sci. 2015;77(2):178–82

- 10 Ali SS, Sharma S, Ahmed T, Sharma R, Jaiswal M, Chaurasia R. Evaluation of self-medication amongst nursing students of Bastar Region: a questionnaire-based study. Int J Pharmacol Res. 2015;5(6):145–9.
- 11 Pereira FSVT, Bucaretchi F, Stephan C, Cordeiro R. Self-medication in children and adolescents. J Pediatr. 2007;83(5):453–8.
- 12 Neto JAC, Sirimarco MT, Choi CMK, Barreto AU, Souza JB. Automedicação entre estudantes da Faculdade de Medicina da Universidade Federal de Juiz de Fora. HU Rev. 2006; 32(3):59–64.
- 13 Sankdia RK, Agrawal M, Rekha PB, Kothari N. A questionnaire-based study regarding the knowledge, attitude and practise of self-medication among second year undergraduate medical students. Int J Pharmacol Clin Sci. 2017;6(1):1–5.
- 14 Schweim H, Ullmann M. Media influence on risk competence in self-medication and selftreatment. Ger Med Sci. 2015;13:10–4.
- 15 Gualano MR, Bert F, Passi S, Stillo M, Galis V, Manzoli L, et al. Use of self-medication among adolescents: a systematic review and meta-analysis. Eur J Public Health. 2015; 25(3):444–50.
- 16 Goud TG, Kumar KP, Ramesh K. A study on self-medication among college students. J Health Sci Med Res. 2014;3(4):77–80.
- 17 Helal RM, Abou-ElWafa HS. Self-medication in university students from the city of Mansoura, Egypt. J Environ Public Health. 2017; 2017:e9145193.
- 18 Abahussain E, Matowe LK, Nicholls PJ. Selfreported medication use among adolescents in Kuwait. Med Princ Pract. 2005;14:161–4.
- 19 Shehnaz SI, Sreedharan J, Khan N, Issa KJ, Arifulla M. Factors associated with self-medication among expatriate high school students: a cross-sectional survey in United Arab Emirates. Epidemiol Biostat Public Health. 2013;10:e8724.

- 20 Westerlund M, Branstad JO, Westerlund T. Medicine-taking behaviour and drug-related problems in adolescents of a Swedish high school. Pharm World Sci Sci. 2008;30:243–50.
- 21 Moraes AC, Delaporte TR, Molena-Fernandes CA, Falcão MC. Factors associated with medicine use and self-medication are different in adolescents. Clinics. 2011;66: 1149–55.
- 22 Silva CH, Giugliani ER. Consumption of medicines among adolescent students: a concern. J Pediatr. 2004;80:326–32.
- 23 Albatti TH, Alawwad S, Aldueb R, Alhoqail R, Almutairi R. The self-medication use among adolescents aged between 13–18 years old: prevalence and behavior, Riyadh, Kingdom of Saudi Arabia, from 2014–2015. Int J Pediatr Adolesc Med. 2017;4(1):19–25.
- 24 Lee CH, Chang FC, Hsu SD, Chi HY, Huang LJ, Yeh MK. Inappropriate self-medication among adolescents and its association with lower medication literacy and substance use. PLoS One. 2017;12(12):1–14.
- 25 Roth-Isigkeit A, Thyen U, Stöven H, Schwarzenberger J, Schmucker P. Pain among children and adolescents: restrictions in daily living and triggering factors. Pediatrics. 2005; 115(2):e152–62.
- 26 Cavaco AM, Sozen-Sahne B, Ulutas-Deniz E, Yegenoglu S. Self-medication and non-prescription drug counseling: illustrating profession uncertainty within Turkish pharmacy practice. Res Soc Adm Pharm. 2018;14(8): 718–26.
- 27 Ferreira RL, Júnior ATT. Estudo sobre a automedicação, o uso irracional de medicamentos e o papel do farmacêutico na sua prevenção. Rev Científica FAEMA. 2018;9:570-6.
- 28 Sousa LCA. Uso racional de medicamentos: algo que precisa ser entendido e trabalhado. Rev Cien Multi Núcleo Conhecimento. 2017; 16:1-6